Bracco, a global leader in diagnostic imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Guerbet's innovation, Elucirem™ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with ...

Women exposed to magnetic resonance imaging (MRI) during the first trimester of pregnancy do not experience an increased risk for harm to the fetus relative to women who were not exposed. The ...

Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...

Please provide your email address to receive an email when new articles are posted on . The FDA is now requiring that gadolinium-based contrast agents carry new label warnings about the risk for ...

Gadolinium-enhanced MRI is associated with an increased risk of stillbirth or neonatal death, as well as rheumatologic, inflammatory, or infiltrative skin conditions. MRI use in the first trimester of ...

New research suggests gadolinium retention may be more widespread and may be present in many more, or possibly all, patients exposed to gadolinium-based contrast agents, according to new research.

Dear Doctor: Not too long ago I developed symptoms of peripheral neuropathy that occurred almost immediately after having an MRI with gadolinium contrast. A physician confirmed that I had retained ...

Reveal's New Manganese-Based MRI Contrast Agent Advances Safer Patient Care · globenewswire.com CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Contrast agents used in MRI scans to improve the ...

In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...